I'm a Texas native covering the latest trends in tech, science and healthcare through explainer pieces on the breaking news team. Previously, I was a Forbes HBCU Scholar writing under the innovation and health and science teams.
Today’s Biden-Netanyahu Call Could Get Tense After WCK Airstrike—But Key Allies Want More Than Tough Talk
$1.2 Billion Powerball Jackpot Is Now The Biggest Of 2024—Here’s What The Winner Could Take Home After TaxesDrug manufacturer Amylyx Pharmaceuticals announced on Thursday plans to remove Relyvrio from the market after lackluster results from a phase III trial, leaving only two other ALS drugs on the market.The process to remove the drug from the market in both Canada and the U.S.
Relyvrio Als Amyotrophic Lateral Sclerosis Als Drugs Relyvrio Als Riluzole Riluzole Als Edaravone Edaravone Als
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Feds: Drug trafficker 'executed' 2 witnesses, including pregnant mother, in San Diego-based drug prosecutionsAuthorities allege Benjamin Madrigal-Birrueta and at least one co-conspirator murdered the two witnesses and buried them in a desert grave in central Washington state
Read more »
Failure of ALS drug puts a spotlight on controversial FDA approvalsA large clinical trial found that Amylyx Pharmaceuticals’ drug to treat ALS doesn’t work, raising questions about the FDA’s process for approving it.
Read more »
Controversial ALS Drug May Be Pulled from Market After Disappointing Trial ResultsFollowing disappointing trial results, the maker of a controversial ALS drug may pull the medication off the market. Amylyx Pharmaceuticals is considering voluntarily withdrawing the drug, Relyvrio/Albrioza, after it failed to help patients in a large follow-up study. The company has decided to pause promotion of the medication and will announce their plans for the drug in the next two months.
Read more »
Amylyx May Pull FDA-Approved ALS Drug After Failed Phase 3 TrialTopline results for the ALS drug Relyvrio show that it failed to meet primary or secondary endpoints. The company says it may voluntarily pull the drug from the market.
Read more »
ALS drug will be pulled from US market after study showed patients didn't benefitTexas Monthly's bracket narrowed the list to a Final Four - and then a winner.
Read more »
ALS drug will be pulled from US market after study showed patients didn't benefitHigh temperatures remain in the 80s.
Read more »